{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-219361","form_type":"8-K","ticker":"BOLT","cik":"0001641281","company_name":"Bolt Biotherapeutics, Inc.","filed_at":"2026-05-12T20:05:16+00:00","discovered_at":"2026-05-12T20:06:00.295312+00:00","generated_at":"2026-05-12T20:08:56.943461+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Bolt Biotherapeutics reports Q1 2026 results; cash $23.9M, BDC-4182 data expected Q3 2026","bullets":["Initial clinical data from BDC-4182 Phase 1/2 study for gastric/gastroesophageal cancer anticipated in Q3 2026.","Cash balance of $23.9M as of March 31, 2026; expected to fund operations into 2027, including dose-escalation completion.","Q1 2026 loss from operations $7.6M vs $12.1M in Q1 2025; R&D expense down to $4.8M from $9.5M.","Two next-generation ISAC programs (CEA and PD-L1) on hold pending BDC-4182 proof-of-concept.","Collaboration revenue fell to $26,000 in Q1 2026 from $1.2M in Q1 2025."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-219361","json":"https://secwatch.observer/filing/0001193125-26-219361.json","markdown":"https://secwatch.observer/filing/0001193125-26-219361.md","text":"https://secwatch.observer/filing/0001193125-26-219361.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1641281/000119312526219361/0001193125-26-219361-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1641281/000119312526219361/bolt-20260512.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-12T20:08:56.943461+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"59daff31b5b0682e03eb9100c2bb9d03af3c6bbc","claim":"Bolt Biotherapeutics, Inc. reported first quarter ended March 31, 2026 results: revenue Total collaboration revenue was $26,000 for the quarter ended March 31, 2026.","evidence_excerpt":"Bolt Biotherapeutics Reports First Quarter 2026 Financial Results and Provides Business Update","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1641281/000119312526219361/0001193125-26-219361-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"first quarter ended March 31, 2026"},{"label":"Revenue","value":"Total collaboration revenue was $26,000 for the quarter ended March 31, 2026"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}